AIM ImmunoTech Inc. — Director's Dealing 2019

Jun 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2019-06-14

Reporting Person: MITCHELL WILLIAM M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-14	Common Stock	J	711	$5.35	Acquired	11161	Direct

Footnotes

F1: Shares issued for 50 percent of Director's Fee for the first half of June, 2019.

F2: Previous balance of the amount of securities owned was divided by 44 due to the 44/1 stock split which occurred on June 11, 2019.